IBD in Pregnancy: Ustekinumab, Vedolizumab Use Appears Safe IBD in Pregnancy: Ustekinumab, Vedolizumab Use Appears Safe
There were no significant differences in pregnancy outcomes and no negative safety signals in postnatal outcomes.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 19, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Johnson & Johnson Reports Q2 2022 Results
New Brunswick, N.J. (July 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2022. “Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, Chief Executive Officer. “I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world.”OVERALL FINANCIAL RESULTS
expand
...
Source: Johnson and Johnson - July 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Which Biologics Stick Longest for Psoriasis?
(MedPage Today) -- Patients stayed longer with guselkumab (Tremfya) for psoriasis treatment than any other biologic drug, while adalimumab (Humira) was dropped the quickest, British registry data indicated.
With ustekinumab (Stelara) chosen arbitrarily... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - July 6, 2022 Category: Dermatology Source Type: news
Two Biologics Work Equally Well for Active Crohn's Disease Two Biologics Work Equally Well for Active Crohn's Disease
For adults with moderate to severe Crohn ' s disease who have never been on a biologic agent, treatment with monotherapy with adalimumab or ustekinumab appear to be equally effective, according to results of the head-to-head SEAVUE trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 16, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Biologics for Crohn's Go Head to Head
(MedPage Today) -- Ustekinumab (Stelara) or adalimumab (Humira) were similarly effective as induction or maintenance therapy for moderate to severe Crohn's disease, according to the randomized SEAVUE trial.
In an intention-to-treat analysis involving... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 14, 2022 Category: Gastroenterology Source Type: news
Loss of Response and Ustekinumab Dose Escalation in IBD Loss of Response and Ustekinumab Dose Escalation in IBD
Can dose escalation improve response to ustekinumab over time in patients with inflammatory bowel diseases?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 25, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Ustekinumab Levels in Pregnant Women With IBD Ustekinumab Levels in Pregnant Women With IBD
This study details the pharmacokinetics of ustekinumab in women with IBD who received the drug during pregnancy as well as in infants exposed in utero.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Johnson & Johnson Reports Q1 2022 Results
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and inno...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Toss Up for Second-Line IBD Tx; Screening for Esophageal Cancer; 100 Colon Polyps
(MedPage Today) -- Effectiveness of vedolizumab (Entyvio) and tofacitinib (Xeljanz) for ulcerative colitis or vedolizumab and ustekinumab (Stelara) for Crohn's disease did not significantly differ among patients who failed on tumor necrosis factor... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 31, 2022 Category: Gastroenterology Source Type: news
Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis
HORSHAM, PENNSYLVANIA, March 22, 2022 – Psoriasis (PsO) can take a physical, psychological, and emotional toll on the more than 8 million Americans living with the disease; and for people of color, there are additional challenges due to limited medical research and education, as well as underrepresentation in clinical studies.1,2,3 This has led to a lack of data and barriers to optimal care for diverse patient populations.2 PsO may also present with less noticeable skin reddening on darker skin tones, which can make it harder for healthcare providers to identify and lead to misdiagnoses in people of color. To help addres...
Source: Johnson and Johnson - March 23, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Ustekinumab or Vedolizumab in Patient's With Crohn's Disease Ustekinumab or Vedolizumab in Patient's With Crohn's Disease
This study indicates that in patients with Crohn ' s disease refractory to anti-TNF, ustekinumab is more effective than vedolizumab as maintenance treatment.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Endoscopic Healing of Crohn's Disease Could Differ by Biologic Endoscopic Healing of Crohn's Disease Could Differ by Biologic
Infliximab biosimilar and adalimumab resulted in better endoscopic healing rates than either vedolizumab or ustekinumab in a post hoc pooled analysis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 3, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Two Studies Shed Light on IBD Treatment After Anti-TNF Failure Two Studies Shed Light on IBD Treatment After Anti-TNF Failure
Separate studies compared vedolizumab with tofacitinib in ulcerative colitis and to ustekinumab in Crohn ' s disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 24, 2022 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Ustekinumab Has Comparatively Low Infection Rate in IBD Ustekinumab Has Comparatively Low Infection Rate in IBD
The biologic was associated with reduced infection risk when compared with anti-TNF agents or tofacitinib in a real-world analysis of nearly 90 million patients.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 11, 2022 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
